FDA Warns Vets of Serious Complications Linked to Common Dog Arthritis Drug Librela

The FDA has issued a warning to veterinarians about serious complications linked to Librela, a common dog arthritis drug. Librela, which was approved by the FDA in May 2023, is a monoclonal antibody used to control pain associated with osteoarthritis in dogs.

The FDA's warning comes after an evaluation of adverse events reported in dogs treated with Librela. These adverse events include severe reactions, such as:

- Ataxia(loss of coordination)
- Seizures
- Neurologic signs, including paresis, recumbency, urinary incontinence, polyuria, and polydipsia
- Death, including euthanasia, in some cases

The FDA encourages veterinarians to report any adverse events or side effects potentially related to the use of Librela. Dog owners are also advised to work closely with their veterinarians to monitor their pets for any signs of adverse reactions.

It's essential for veterinarians to carefully evaluate the potential benefits and risks of Librela before administering it to dogs. Additionally, veterinarians should advise owners about the possible adverse events and side effects before using the drug.

https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-monoclonal-antibody-dogs-osteoarthritis-pain